News & Updates

Adjuvant atezolizumab improves DFS in early-stage NSCLC
Adjuvant atezolizumab improves DFS in early-stage NSCLC
27 Oct 2021 byRoshini Claire Anthony

In patients with completely resected stage II–IIIA non-small-cell lung cancer (NSCLC) who had previously received adjuvant cisplatin chemotherapy, adjuvant atezolizumab extended disease-free survival (DFS), particularly in those with PD-L1 expression 1 percent on tumour cells, interim results of the phase III IMpower010 trial showed.

Adjuvant atezolizumab improves DFS in early-stage NSCLC
27 Oct 2021
Overweight, obesity during pregnancy up offspring’s NAFLD risk
Overweight, obesity during pregnancy up offspring’s NAFLD risk
27 Oct 2021
Chronic constipation not a risk factor for later colorectal cancer
Chronic constipation not a risk factor for later colorectal cancer
27 Oct 2021

Individuals with chronic constipation do not seem to be at increased risk of developing subsequent colorectal cancer as compared with their peers who do not have the gastrointestinal condition, as reported in a study.

Chronic constipation not a risk factor for later colorectal cancer
27 Oct 2021